Prothrombin Time Interpretation and Management

Introduction to Prothrombin Time

A PT ratio >1.4 (or INR >1.4 for non-warfarin patients) is generally considered prolonged and warrants investigation, though the clinical significance depends entirely on the context—whether the patient is on warfarin, has liver disease, or requires an invasive procedure 1, 2

A PT ratio >1.4 times the normal control is considered abnormal and requires evaluation for underlying causes 1, 2
For invasive procedures, a PT ratio >1.4 is a relative contraindication and should prompt correction or procedure deferral 1, 2

The American College of Cardiology recommends a therapeutic range: INR 2.0-3.0 for most indications (atrial fibrillation, DVT, PE) 5, 6, 2
A higher therapeutic range: INR 2.5-3.5 is recommended for mechanical prosthetic heart valves 2
Subtherapeutic: INR <2.0 increases thrombosis risk 2
Concerning: INR >3.0 increases bleeding risk 2
High risk: INR >5.0 requires dose adjustment and close monitoring 2
Very high risk: INR >9.0 poses serious bleeding risk and necessitates immediate intervention 2

The INR is invalid in liver disease because the INR scale was calibrated using warfarin patients, not cirrhosis patients 3, 7
A prolonged PT/INR in cirrhosis does NOT predict bleeding risk due to rebalanced hemostasis 3, 7
The MELD score uses INR for disease severity but it does not predict bleeding risk spontaneously or with procedures 3

INR does not predict bleeding risk in patients with or without cirrhosis undergoing procedures 3
Randomized trials show no reduction in bleeding when prophylactic plasma is given to correct INR values in periprocedural, critically ill, and liver disease patients 3
For procedures, defer if INR ≥2.0 in warfarin patients; for non-warfarin patients, PT ratio >1.4 is a relative contraindication 1, 2

PT prolongation in critical illness does not contraindicate thromboprophylaxis 10
Subtle PT changes may not be detected if reported as INR rather than seconds or ratio 8, 9

There is NO high-quality evidence that plasma transfusions reduce bleeding in nonbleeding patients with incidentally abnormal INRs 3
A normal INR has poor sensitivity for bleeding disorders and provides false reassurance in patients who may require factor replacement for inherited or acquired bleeding tendencies 3

Determine if patient is on warfarin: if yes, use INR thresholds; if no, proceed to check PT ratio 3, 10
Check PT ratio: if ≤1.4, likely normal variation; if >1.4, proceed to assess clinical context 3, 2
Assess clinical context: consider liver disease, procedure planned, critical illness/COVID-19, or unclear situations 3, 7, 1, 2, 8, 9, 10